Ameritas Investment Partners’s Accelerate Diagnostics AXDX Stock Holding History

Ameritas Investment Partners’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-229	Closed	-$3K	–	3076
2022 Q1	$3K	Hold	229	–	–	﹤0.01%	3022
2021 Q4	$12K	Hold	229	–	–	﹤0.01%	2834
2021 Q3	$13K	Hold	229	–	–	﹤0.01%	2861
2021 Q2	$18K	Hold	229	–	–	﹤0.01%	2779
2021 Q1	$19K	Hold	229	–	–	﹤0.01%	2578
2020 Q4	$17K	Hold	229	–	–	﹤0.01%	2550
2020 Q3	$24K	Hold	229	–	–	﹤0.01%	2274
2020 Q2	$35K	Hold	229	–	–	﹤0.01%	2037
2020 Q1	$19K	Hold	229	–	–	﹤0.01%	2200
2019 Q4	$39K	Hold	229	–	–	﹤0.01%	2051
2019 Q3	$42K	Hold	229	–	–	﹤0.01%	1986
2019 Q2	$52K	Hold	229	–	–	﹤0.01%	1885
2019 Q1	$48K	Hold	229	–	–	﹤0.01%	1903
2018 Q4	$26K	Hold	229	–	–	﹤0.01%	2179
2018 Q3	$52K	Hold	229	–	–	﹤0.01%	1973
2018 Q2	$51K	Hold	229	–	–	﹤0.01%	1976
2018 Q1	$52K	Hold	229	–	–	﹤0.01%	1900
2017 Q4	$60K	Hold	229	–	–	﹤0.01%	1823
2017 Q3	$52K	Hold	229	–	–	﹤0.01%	1873
2017 Q2	$63K	Buy	229 +30	+15%	+$8.13K	﹤0.01%	1748
2017 Q1	$48K	Buy	+199	New	+$45.5K	﹤0.01%	1874

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Ameritas Investment Partners's AXDX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 229 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in AXDX in Q1 2017 and held it in 21 quarters. The position peaked at $63K in Q2 2017. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

Ameritas Investment Partners reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 229 Accelerate Diagnostics shares in Q2 2022, an estimated $3K.
Ameritas Investment Partners first reported a position in Accelerate Diagnostics in Q1 2017 and held it in 21 quarters.
Ameritas Investment Partners's Accelerate Diagnostics position peaked at $63K in Q2 2017.
74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.